Literature DB >> 2304424

Systemic Castleman's disease in association with Evan's syndrome and vitiligo.

J H Marsh1, D S Colbourn, V Donovan, H Staszewski.   

Abstract

Systemic Castleman's disease is a lymphoproliferative disorder which has been associated with autoimmune phenomena. We report a case of the plasma cell variant of Castleman's disease that was associated with autoimmune hemolytic anemia and autoimmune thrombocytopenia (Evan's syndrome), and vitiligo, the association of which has not been previously reported.

Entities:  

Mesh：

Year:  1990        PMID： 2304424     DOI： 10.1002/mpo.2950180216

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN： 0098-1532


  6 in total

1.  Sjögren's and plasma cell variant Castleman disease: a case report.

Authors:  Yvonne A Dei-Adomakoh; Leslie Quarcoopome; Afua D Abrahams; Catherine I Segbefia; Dzifa I Dey
Journal:  Ghana Med J       Date:  2018-03

2.  Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids.

Authors:  Shiho Fujiwara; Hiromi Mochinaga; Hirotomo Nakata; Koichi Ohshima; Masanori Matsumoto; Mitsuhiro Uchiba; Yoshiki Mikami; Hiroyuki Hata; Yutaka Okuno; Hiroaki Mitsuya; Kisato Nosaka
Journal:  Int J Hematol       Date:  2016-03-15       Impact factor: 2.490

Review 3.  Update and new approaches in the treatment of Castleman disease.

Authors:  Kah-Lok Chan; Stephen Lade; H Miles Prince; Simon J Harrison
Journal:  J Blood Med       Date:  2016-08-03

4.  Acute myelogenous leukemia M5b developed during clinical remission of Castleman disease.

Authors:  Akira Tomonari; Naoki Shirafuji; Arinobu Tojo; Tohru Iseki; Jun Ooi; Itaru Komiya; Kenzaburo Tani; Shigetaka Asano
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.319

5.  Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura.

Authors:  Ruchi Sood; Harris C Taylor; Hamed Daw
Journal:  Case Rep Hematol       Date:  2013-10-02

6.  Rituximab therapy in a patient with autoimmune hemolytic anemia and immune thrombocytopenia associated with chronic lymphocytic leukemia.

Authors:  Aamer Aleem
Journal:  Ann Saudi Med       Date:  2008 Sep-Oct       Impact factor: 1.526
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.